C HICAGO -- The investigational CD40 agonist mitazalimab and modified FOLFIRINOX demonstrated encouraging activity in ...

Viking Therapeutics ( VKTX 4.71%) is an anomaly of sorts. Despite another underwhelming year for biotech stocks, the ...

A new study in mice suggests that blocking the GLP-1 receptor may help defend against colorectal cancer, begging the question ...

“Taste perception can vary significantly from person to person, limiting the generalizability of our results,” she said.

The US FDA has approved once-daily Onyda XR as the first liquid, nonstimulant treatment for attention-deficit/hyperactivity disorder (ADHD).

(RTTNews) - Madrigal Pharmaceuticals, Inc. (MDGL), Thursday announced that its Phase 3 MAESTRO-NASH biopsy trial using Rezdiffra achieved both fibrosis improvement and NASH resolution primary ...

New research argues that the oral alternative to injected semaglutide could also help improve the symptoms of diabetes and ...

Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of ...

Narcolepsy type 1 is a rare, chronic central nervous system disorder defined by a loss of orexin neurons, with common ...

From 2020 to 2023, the number of individuals ages 12 to 25 years who received a prescription for the diabetes or weight-loss ...

A new research paper titled "Serine racemase expression profile in the prefrontal cortex and hippocampal subregions during ...

Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor ...